CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors
Kidney transplants (KT) from hepatitis C (HCV) viremic donors to HCV negative recipients has shown promising renal outcomes, however, high incidence of cytomegalovirus (CMV) viremia were reported. We performed a prospective cohort study of 52 HCV negative KT recipients from Methodist University Hospital including 41 receiving transplants from HCV aviremic donors and 11 from HCV viremic donors. CMV specific CD4+ and CD8 + T cell immunity was measured by intracellular flow cytometry assay. Primary outcome was the development of positive CMV specific CD4+ and CD8 + T cell immune response in the entire cohort and each subgroup. The association between donor HCV status and CMV specific CD4+ and CD8 + T cell immune response was analyzed by Cox proportional hazard models. Mean recipient age was 48 ± 13 years, with 73% male and 82% African American. Positive CMV specific CD4+ and CD8 + T cell immune response was found in 53% and 47% of the cohort at 1 month, 65% and 70% at 2 months, 80% and 75% at 4 months, 89% and 87% at 6 months, and 94% and 94% at 9 months post-transplant, respectively. There was no significant difference in the incidence of positive CMV specific T cell immune response between recipients of transplants from HCV aviremic donors compared to HCV viremic donors in unadjusted (for CD8+: HR = 1.169, 95%CI: 0.521-2.623; for CD4+: HR = 1.208, 95%CI: 0.543-2.689) and adjusted (for CD8+: HR = 1.072, 95%CI: 0.458-2.507; for CD4+: HR = 1.210, 95%CI: 0.526-2.784) Cox regression analyses. HCV viremia in donors was not associated with impaired development of CMV specific T cell immunity in this cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Renal failure - 44(2022), 1 vom: 01. Dez., Seite 831-841 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Azhar, Ambreen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 19.05.2022 Date Revised 27.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/0886022X.2022.2072744 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340745983 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340745983 | ||
| 003 | DE-627 | ||
| 005 | 20231226010152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/0886022X.2022.2072744 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340745983 | ||
| 035 | |a (NLM)35546431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Azhar, Ambreen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2022 | ||
| 500 | |a Date Revised 27.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Kidney transplants (KT) from hepatitis C (HCV) viremic donors to HCV negative recipients has shown promising renal outcomes, however, high incidence of cytomegalovirus (CMV) viremia were reported. We performed a prospective cohort study of 52 HCV negative KT recipients from Methodist University Hospital including 41 receiving transplants from HCV aviremic donors and 11 from HCV viremic donors. CMV specific CD4+ and CD8 + T cell immunity was measured by intracellular flow cytometry assay. Primary outcome was the development of positive CMV specific CD4+ and CD8 + T cell immune response in the entire cohort and each subgroup. The association between donor HCV status and CMV specific CD4+ and CD8 + T cell immune response was analyzed by Cox proportional hazard models. Mean recipient age was 48 ± 13 years, with 73% male and 82% African American. Positive CMV specific CD4+ and CD8 + T cell immune response was found in 53% and 47% of the cohort at 1 month, 65% and 70% at 2 months, 80% and 75% at 4 months, 89% and 87% at 6 months, and 94% and 94% at 9 months post-transplant, respectively. There was no significant difference in the incidence of positive CMV specific T cell immune response between recipients of transplants from HCV aviremic donors compared to HCV viremic donors in unadjusted (for CD8+: HR = 1.169, 95%CI: 0.521-2.623; for CD4+: HR = 1.208, 95%CI: 0.543-2.689) and adjusted (for CD8+: HR = 1.072, 95%CI: 0.458-2.507; for CD4+: HR = 1.210, 95%CI: 0.526-2.784) Cox regression analyses. HCV viremia in donors was not associated with impaired development of CMV specific T cell immunity in this cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CMV specific T cell immune response | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Tsujita, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Talwar, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Balaraman, Vasanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Bhalla, Anshul |e verfasserin |4 aut | |
| 700 | 1 | |a Eason, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Nouer, Simonne S |e verfasserin |4 aut | |
| 700 | 1 | |a Sumida, Keiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Remport, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Isaac E |e verfasserin |4 aut | |
| 700 | 1 | |a Griffin, Randi |e verfasserin |4 aut | |
| 700 | 1 | |a Rofaiel, George |e verfasserin |4 aut | |
| 700 | 1 | |a Molnar, Miklos Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Renal failure |d 1995 |g 44(2022), 1 vom: 01. Dez., Seite 831-841 |w (DE-627)NLM012950394 |x 1525-6049 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2022 |g number:1 |g day:01 |g month:12 |g pages:831-841 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/0886022X.2022.2072744 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2022 |e 1 |b 01 |c 12 |h 831-841 | ||